(Q43952836)

English

Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Rec

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Rec (English)

1 reference

Europe PubMed Central

28 November 2017

0 references

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Benjamin J. Luft

13

object named as

Benjamin J Luft

1 reference

Europe PubMed Central

28 November 2017

Catherine Leport

3

object named as

Catherine Leport

1 reference

Europe PubMed Central

28 November 2017

author name string

Keith Chirgwin

1

1 reference

Europe PubMed Central

28 November 2017

Richard Hafner

2

1 reference

Europe PubMed Central

28 November 2017

Jack Remington

4

1 reference

Europe PubMed Central

28 November 2017

Janet Andersen

5

1 reference

Europe PubMed Central

28 November 2017

Elizabeth M Bosler

6

1 reference

Europe PubMed Central

28 November 2017

Clemente Roque

7

1 reference

Europe PubMed Central

28 November 2017

Natasa Rajicic

8

1 reference

Europe PubMed Central

28 November 2017

Vincent McAuliffe

9

1 reference

Europe PubMed Central

28 November 2017

Philippe Morlat

10

1 reference

Europe PubMed Central

28 November 2017

D T Jayaweera

11

1 reference

Europe PubMed Central

28 November 2017

Jean-Louis Vilde

12

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

1 May 2002

1 reference

Europe PubMed Central

28 November 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

28 November 2017

34

1 reference

Europe PubMed Central

28 November 2017

9

1 reference

Europe PubMed Central

28 November 2017

1243-1250

1 reference

Europe PubMed Central

28 November 2017

Toxoplasmic encephalitis in AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Doxycycline and pyrimethamine for toxoplasmic encephalitis.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

1 reference

https://api.crossref.org/works/10.1086%2F339551

21 January 2018

Identifiers

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43952836&oldid=2104608508"